{
    "markdown": "<a id='4e8552fa-3fd4-434f-b8e7-8e0f319b714e'></a>\n\n<::Takeda logo with an oval shape and arrows.\n: figure::>\n\n<a id='0c3e3d93-f85c-4985-84bf-82230494d675'></a>\n\n## Call for Reporting\nPlease report suspected adverse reactions with pioglitazone to the MHRA through the Yellow Card Scheme online at www.yellowcard.gov.uk. Alternatively, prepaid Yellow Cards for reporting are available:\n* upon request by mail: \"FREEPOST YELLOW CARD\"\n* at the back of the British National Formulary (BNF)\n* by telephoning the Commission of Human Medicines (CHM) free phone line: 0800-731-6789\n* or by electronic download through the MHRA website (http://yellowcard.mhra.gov.uk/downloads/)\n\nSuspected adverse drug reactions may also be reported to Takeda's Pharmacovigilance Department at: Takeda UK Ltd on Tel; 01628 537 900 or via e-mail to Drugsafety@takeda.co.uk. When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset and treatment dates.\n\n## Further information\nShould you have any questions or require additional information, please call Medical Information at Takeda UK Ltd on Tel: 01628 537 900 or send an e-mail to Medinfo@takeda.co.uk.\n\n<a id='ad2acc57-9409-46f5-9c69-134d67599852'></a>\n\n<::attestation: Signature\nSignature: legible (Charles Baum)\nReadable Text: Dr. C. Baum MD\nEuropean Medical Director\nTakeda Pharmaceuticals Europe Limited\nA handwritten signature positioned above typed text identifying the signatory and their professional details.::>\n\n<a id='23022b9c-d9d2-438b-a4fd-7a08e277270d'></a>\n\nConfidential - Subject to Protective Order TAK-TYNANJ-00213200\n\n<a id='41aa6f2b-5621-452b-bd7c-597b59e4c293'></a>\n\nSource: https://www.indupP5441-00003s.ucsf.edu/docs/psjf0226",
    "chunks": [
        {
            "markdown": "<a id='4e8552fa-3fd4-434f-b8e7-8e0f319b714e'></a>\n\n<::Takeda logo with an oval shape and arrows.\n: figure::>",
            "type": "figure",
            "id": "4e8552fa-3fd4-434f-b8e7-8e0f319b714e",
            "grounding": {
                "box": {
                    "left": 0.10881112515926361,
                    "top": 0.045840803533792496,
                    "right": 0.25262635946273804,
                    "bottom": 0.08835908770561218
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='0c3e3d93-f85c-4985-84bf-82230494d675'></a>\n\n## Call for Reporting\nPlease report suspected adverse reactions with pioglitazone to the MHRA through the Yellow Card Scheme online at www.yellowcard.gov.uk. Alternatively, prepaid Yellow Cards for reporting are available:\n* upon request by mail: \"FREEPOST YELLOW CARD\"\n* at the back of the British National Formulary (BNF)\n* by telephoning the Commission of Human Medicines (CHM) free phone line: 0800-731-6789\n* or by electronic download through the MHRA website (http://yellowcard.mhra.gov.uk/downloads/)\n\nSuspected adverse drug reactions may also be reported to Takeda's Pharmacovigilance Department at: Takeda UK Ltd on Tel; 01628 537 900 or via e-mail to Drugsafety@takeda.co.uk. When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset and treatment dates.\n\n## Further information\nShould you have any questions or require additional information, please call Medical Information at Takeda UK Ltd on Tel: 01628 537 900 or send an e-mail to Medinfo@takeda.co.uk.",
            "type": "text",
            "id": "0c3e3d93-f85c-4985-84bf-82230494d675",
            "grounding": {
                "box": {
                    "left": 0.09304842352867126,
                    "top": 0.09900155663490295,
                    "right": 0.8265283107757568,
                    "bottom": 0.45026692748069763
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='ad2acc57-9409-46f5-9c69-134d67599852'></a>\n\n<::attestation: Signature\nSignature: legible (Charles Baum)\nReadable Text: Dr. C. Baum MD\nEuropean Medical Director\nTakeda Pharmaceuticals Europe Limited\nA handwritten signature positioned above typed text identifying the signatory and their professional details.::>",
            "type": "attestation",
            "id": "ad2acc57-9409-46f5-9c69-134d67599852",
            "grounding": {
                "box": {
                    "left": 0.09363026916980743,
                    "top": 0.49268579483032227,
                    "right": 0.44691574573516846,
                    "bottom": 0.6188358068466187
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='23022b9c-d9d2-438b-a4fd-7a08e277270d'></a>\n\nConfidential - Subject to Protective Order TAK-TYNANJ-00213200",
            "type": "text",
            "id": "23022b9c-d9d2-438b-a4fd-7a08e277270d",
            "grounding": {
                "box": {
                    "left": 0.0478956401348114,
                    "top": 0.9562129378318787,
                    "right": 0.8987494707107544,
                    "bottom": 0.9754071831703186
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='41aa6f2b-5621-452b-bd7c-597b59e4c293'></a>\n\nSource: https://www.indupP5441-00003s.ucsf.edu/docs/psjf0226",
            "type": "marginalia",
            "id": "41aa6f2b-5621-452b-bd7c-597b59e4c293",
            "grounding": {
                "box": {
                    "left": 0.2213647961616516,
                    "top": 0.9792504906654358,
                    "right": 0.7820858359336853,
                    "bottom": 0.9999808669090271
                },
                "page": 0
            }
        }
    ],
    "splits": [
        {
            "class": "full",
            "identifier": "full",
            "pages": [
                0
            ],
            "markdown": "<a id='4e8552fa-3fd4-434f-b8e7-8e0f319b714e'></a>\n\n<::Takeda logo with an oval shape and arrows.\n: figure::>\n\n<a id='0c3e3d93-f85c-4985-84bf-82230494d675'></a>\n\n## Call for Reporting\nPlease report suspected adverse reactions with pioglitazone to the MHRA through the Yellow Card Scheme online at www.yellowcard.gov.uk. Alternatively, prepaid Yellow Cards for reporting are available:\n* upon request by mail: \"FREEPOST YELLOW CARD\"\n* at the back of the British National Formulary (BNF)\n* by telephoning the Commission of Human Medicines (CHM) free phone line: 0800-731-6789\n* or by electronic download through the MHRA website (http://yellowcard.mhra.gov.uk/downloads/)\n\nSuspected adverse drug reactions may also be reported to Takeda's Pharmacovigilance Department at: Takeda UK Ltd on Tel; 01628 537 900 or via e-mail to Drugsafety@takeda.co.uk. When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset and treatment dates.\n\n## Further information\nShould you have any questions or require additional information, please call Medical Information at Takeda UK Ltd on Tel: 01628 537 900 or send an e-mail to Medinfo@takeda.co.uk.\n\n<a id='ad2acc57-9409-46f5-9c69-134d67599852'></a>\n\n<::attestation: Signature\nSignature: legible (Charles Baum)\nReadable Text: Dr. C. Baum MD\nEuropean Medical Director\nTakeda Pharmaceuticals Europe Limited\nA handwritten signature positioned above typed text identifying the signatory and their professional details.::>\n\n<a id='23022b9c-d9d2-438b-a4fd-7a08e277270d'></a>\n\nConfidential - Subject to Protective Order TAK-TYNANJ-00213200\n\n<a id='41aa6f2b-5621-452b-bd7c-597b59e4c293'></a>\n\nSource: https://www.indupP5441-00003s.ucsf.edu/docs/psjf0226",
            "chunks": [
                "4e8552fa-3fd4-434f-b8e7-8e0f319b714e",
                "0c3e3d93-f85c-4985-84bf-82230494d675",
                "ad2acc57-9409-46f5-9c69-134d67599852",
                "23022b9c-d9d2-438b-a4fd-7a08e277270d",
                "41aa6f2b-5621-452b-bd7c-597b59e4c293"
            ]
        }
    ],
    "grounding": {
        "4e8552fa-3fd4-434f-b8e7-8e0f319b714e": {
            "box": {
                "left": 0.10881112515926361,
                "top": 0.045840803533792496,
                "right": 0.25262635946273804,
                "bottom": 0.08835908770561218
            },
            "page": 0,
            "type": "chunkFigure"
        },
        "0c3e3d93-f85c-4985-84bf-82230494d675": {
            "box": {
                "left": 0.09304842352867126,
                "top": 0.09900155663490295,
                "right": 0.8265283107757568,
                "bottom": 0.45026692748069763
            },
            "page": 0,
            "type": "chunkText"
        },
        "ad2acc57-9409-46f5-9c69-134d67599852": {
            "box": {
                "left": 0.09363026916980743,
                "top": 0.49268579483032227,
                "right": 0.44691574573516846,
                "bottom": 0.6188358068466187
            },
            "page": 0,
            "type": "chunkAttestation"
        },
        "23022b9c-d9d2-438b-a4fd-7a08e277270d": {
            "box": {
                "left": 0.0478956401348114,
                "top": 0.9562129378318787,
                "right": 0.8987494707107544,
                "bottom": 0.9754071831703186
            },
            "page": 0,
            "type": "chunkText"
        },
        "41aa6f2b-5621-452b-bd7c-597b59e4c293": {
            "box": {
                "left": 0.2213647961616516,
                "top": 0.9792504906654358,
                "right": 0.7820858359336853,
                "bottom": 0.9999808669090271
            },
            "page": 0,
            "type": "chunkMarginalia"
        }
    },
    "metadata": {
        "filename": "psjf0226_3.png",
        "org_id": null,
        "page_count": 1,
        "duration_ms": 5883,
        "credit_usage": 3.0,
        "job_id": "xsa4odqzexct9zvpq5b14ulf0",
        "version": "dpt-2-20250919"
    }
}